Archemix, Dicerna Sign Agreement To Develop Aptamer-Dicer RNAi Drugs

Archemix and Dicerna have entered into an agreement to develop aptamer-DsiRNA therapeutics. Both the firms will work collaboratively on the R&D activities.

The agreement includes an option for Dicerna to obtain exclusive rights to develop and commercialize aptamer-DsiRNA therapeutics, generated during the collaboration.

Kenneth Bate, president and CEO of Archemix, said: “This collaboration showcases how our proprietary aptamer technology can be used in conjunction with other therapeutic modalities and we look forward to beginning this exciting work with Dicerna.

“This agreement leverages our aptamer expertise and intellectual property estate with Dicerna’s expertise in RNAi therapeutics to develop a technology with the potential to mediate targeted delivery, intracellular uptake and gene silencing,” he added.